Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

REPL vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REPL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

REPL Overall Winner 6-Pillar Tally: REPL 3 – 2 ENTA (1 Tie) Matrix Metrics: REPL 5 – 5 ENTA

As of Nov 16, 2026, Replimune Group, Inc. (REPL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). REPL carries a Unified Composite Score of 27.4/100 (SELL) at $21.41 (N/M Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. REPL 27.4/100 SELL), REPL captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY).
  • Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 69.6); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REPL vs ENTA
REPL NASDAQ Head-to-Head Winner
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$21.41
-2.19% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.08β · 100% Vol
Unified Composite Score
27.4 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.3% over 20 days), RSI 70
RSI-14: 69.6 · SMA20: $17.92 · SMA50: $14.89
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.67
-2.91% 1D
Market Cap $320.1M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.88β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (REPL 3 – 2 ENTA)

Columns: Metric · REPL · ENTA
1. Valuation Multiples ENTA
Forward P/E N/M 44.0x
Trailing P/E N/M 44.0x
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale REPL
Revenue Growth (YoY) +0.0% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) N/A $65M
Market Cap $2.1B $320.1M
3. Profitability & Quality REPL
Gross Margin N/A 100.0%
Operating Margin 0.0% -90.0%
Net Profit Margin 0.0% -96.9%
Return on Equity (ROE) -115.8% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$246M -$37M
Cash Flow Margin N/A -56.6%
Net Cash / Leverage $181M Net Cash $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning REPL
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 220.4% (23rd %ile) 78.7% (11th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REPL (5) vs ENTA (5)
Institutional Metric REPL ENTA Criterion Row Edge
Market Capitalization
Scale
$2.1B $320.1M Larger Scale REPL
Trailing P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Forward P/E Ratio
Valuation
N/M 44.0x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
+0.0% -21.6% Higher Growth REPL
Operating Margin (TTM)
Profitability
0.0% -90.0% Higher Margin REPL
Net Profit Margin
Profitability
0.0% -96.9% Higher Margin REPL
Return on Equity (ROE)
Capital Efficiency
-115.8% -70.1% Higher ROE ENTA
52-Week Range Position
Momentum
90% ($2–$24) 9% ($10–$17) Stronger Trend REPL
Beta / 30D Volatility
Risk Regime
2.08β · 100% Vol 0.88β · 58% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
27.4 / 100 (SELL) 46.2 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
N/A $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$246M ($181M Net Cash) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REPL +101.02 pp
REPL: +97.15% · ENTA: -3.87%
3M Horizon REPL +57.19 pp
REPL: +37.42% · ENTA: -19.77%
6M Horizon REPL +330.58 pp
REPL: +310.15% · ENTA: -20.43%
1Y Horizon REPL +147.38 pp
REPL: +138.42% · ENTA: -8.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs ENTA. Trailing 12-month operating profitability (REPL 0.0% vs ENTA -90.0%) and valuation multiples (REPL N/M vs ENTA 44.0x Forward P/E) are benchmarked directly in Pillar 4 below.

REPL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-115.8% · N/M
ENTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$65M
Gross Margin100.0%
Op. Margin-90.0%
ROE / Fwd P/E-70.1% · 44.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REPL BREAKOUT
98d in phase · OBV NEUTRAL
Current IV 220.4%
IV Percentile 23rd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact REPL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REPL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $320.1M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REPL vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Replimune Group, Inc. (REPL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). REPL carries a Unified Composite Score of 27.4/100 (SELL) at $21.41 (N/M Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. REPL 27.4/100 SELL), REPL captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY). Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 69.6); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REPL leads the Growth & Scale pillar: REPL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). On trailing 12-month operating scale, REPL generates N/A in USD-normalized revenue versus $65M for ENTA. In operating R&D and SG&A reinvestment, REPL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

ENTA screens cheaper on headline valuation multiples. REPL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.2x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REPL (-115.8% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, REPL carries 220.4% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.08β · 100% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.88β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.